Galena to target Abstral as market leader for cancer pain

Tweet Galena Biopharma (NASDAQ:GALE) plans to make its recently acquired Abstral sublingual tablets the market leader for the treatment of breakthrough cancer pain (BTcP) in the U.S., matching the product’s performance in Europe. “Abstral is the latest and best-in-class drug for this indication,” president and CEO Mark Ahn says in an interview with BioTuesdays.com, noting [...]

Roth ups Galena price target to $7

Tweet Roth Capital Partners has raised its price target for “buy-rated” Galena Biopharma (NASDAQ:GALE) to $7 from $5, after the company’s acquired to the rights for cancer breakthrough product, Abstral, from Orexo, with plans to launch in the U.S. in the fourth quarter this year. “We believe the acquisition is encouraging as it could potential [...]

Roth starts TG Therapeutics at buy

Tweet Roth Capital Partners has initiated coverage of TG Therapeutics (OTCBB:TGTX) with a “buy” rating and 12-month price target of $13, saying that TG is well positioned in the growing hematology/oncology space by addressing validated targets and with encouraging early clinical data in hand. The stock closed at $4.79 on Thursday. “We view TG as [...]

Roth starts Verastem at buy

Tweet Roth Capital Partners has initiated coverage of Verastem (NASDAQ:VSTM) with a “buy” rating and 12-month price target of $18, saying that it considers Versatem an intriguing oncology play, built on the innovative notion of targeting cancer stem cells (CSCs). The stock closed at $9.20 on Tuesday. “We view Verastem as an exciting opportunity with [...]

Roth starts Cytori Therapeutics at buy

Tweet Roth Capital Partners has initiated coverage of Cytori Therapeutics (NASDAQ:CYTX) with a “buy” rating and a 12-month price target of $8, saying “substantial upside remains at the current valuation.” The stock closed at $2.69 on Tuesday. Cytori is an emerging cell therapy company focusing on the development of adipose-derived stem and regenerative cells (ADRCs) [...]

Ladenburg, Roth up price targets on Keryx

Tweet Ladenburg Thalmann and Roth Capital Partners each raised its price target on “buy-rated” Keryx Biopharmaceuticals (NASDAQ:KERX) to $15 after the company announced that the long-term safety and efficacy Phase 3 study with Zerenex met its primary and key secondary endpoints. Shares of Keryx are changing hands at $8.27, up $2.21, in trading Tuesday morning [...]

Roth adds Celldex to focus list

Tweet Roth Capital Partners has added “buy-rated” Celldex Therapeutics (NASDAQ:CLDX) to its “focus list as a biotech Top Pick for 2013” and raised its price target to $16 from $11, saying the company is solidifying its position as a premier cancer immunotherapy company with a broad pipeline. Shares of Celldex closed at $7.32 on Monday. [...]

Roth ups TearLab price target to $7

Tweet Roth Capital Partners has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $7 from $5, saying market awareness of TearLab is on the rise and TearLab system placements are expected to be strong in 2013. The stock closed at $5.48 on Monday. “Our valuation analysis now centers on our revenue projection for [...]

Roth raises Peregrine price target to $4

Tweet Roth Capital Partners has raised its price target on “buy-rated” Peregrine Pharmaceuticals (NASDAQ:PPHM) to $4 from $2.70, saying it believes the bavituximab program in lung cancer is back on track, which should result in multiple stock driving catalysts in 2013. The stock closed at $2.10 on Friday. With the important analyses almost completed in [...]

Roth starts ImmunoCellular at buy

Tweet Roth Capital Partners has initiated coverage of ImmunoCellular Therapeutics (NASDAQ:IMUC) with a “buy” rating and $6 price target. The stock closed at $2.03 on Wednesday. “We recommend that investors own shares of ImmunoCellular, with important catalysts expected in 2013 and also based on our projection that the company will become a leading player in [...]

Next Page »